Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform

Journal of Proteomics

Volumn 145, Issue , 2016, Pages 197-206

  Callejón Leblic, Belén ^a   García Barrera, Tamara ^a   Grávalos Guzmán, Jesús ^b   Pereira Vega, Antonio ^b   Gómez Ariza, José Luis ^a  

^a UNIVERSITY OF HUELVA   (Spain)

^b HOSPITAL UNIVERSITARIO JUAN RAMÓN JIMÉNEZ   (Spain)

Author keywords

Biomarkers; Bronchoalveolar fluid; Direct infusion mass spectrometry; Gas chromatography mass spectrometry; Lung cancer; Metabolomics

Indexed keywords

ACETIC ACID; ACETYLCARNITINE; ACETYLCHOLINE; ADENINE; ARGININE; BENZOIC ACID; CARNITINE; CHOLINE; CREATINE; GALACTOSE; GLUTAMIC ACID; GLUTAMINE; GLYCEROL; GLYCEROPHOSPHORYLCHOLINE; INOSINE; ISOCITRIC ACID; LACTIC ACID; LYSOPHOSPHOLIPID; OLEIC ACID; PALMITIC ACID; PHOSPHOETHANOLAMINE; PHOSPHORIC ACID; PHOSPHORYLCHOLINE; PLASMALOGEN; PYROGLUTAMIC ACID; SERINE; STEARIC ACID; TUMOR MARKER; UREA; VALINE;

AGED; AMINO ACID METABOLISM; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD SAMPLING; BRONCHOALVEOLAR LAVAGE FLUID; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; LOWER RESPIRATORY TRACT; LUNG CANCER; LUNG PARENCHYMA; MALE; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TIME TO TREATMENT; URINE SAMPLING; ADULT; CASE CONTROL STUDY; CHEMISTRY; LUNG TUMOR; METABOLISM; MIDDLE AGED; PROCEDURES;

ADULT; AGED; BIOMARKERS, TUMOR; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLYCEROL; HUMANS; LUNG NEOPLASMS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MIDDLE AGED; PHOSPHORIC ACIDS;

EID: 84973171653     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2016.05.030     Document Type: Article

References (62)

1. [1] Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 380 (2012), 2095–2128, 10.1016/S0140-6736(12)61728-0.
2. [2] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J. Clin. 61 (2011), 69–90, 10.3322/caac.20107.
3. [3] Chen, Y., Ma, Z., Li, A., Li, H., Wang, B., Zhong, J., et al. Metabolomic Profiling of Human Serum in Lung Cancer Patients Using Liquid Chromatography / Hybrid Quadrupole Time-of-Flight Mass Spectrometry and Gas Chromatography / Mass Spectrometry. 2015, 705–718, 10.1007/s00432–014–1846-5.
4. [4] Lokhov, P.G., Kharybin, O.N., Archakov, A.I., Diagnosis of lung cancer based on direct-infusion electrospray mass spectrometry of blood plasma metabolites. Int. J. Mass Spectrom. 309 (2012), 200–205, 10.1016/j.ijms.2011.10.002.
5. [5] Hocker, J.R., Peyton, M.D., Lerner, M.R., Mitchell, S.L., Lightfoot, S.A., Lander, T.J., et al. Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry. Lung Cancer 74 (2011), 206–211, 10.1016/j.lungcan.2011.03.014.
6. [6] Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008), 71–96, 10.3322/CA.2007.0010.
7. [7] Hori, S., Nishiumi, S., Kobayashi, K., Shinohara, M., Hatakeyama, Y., Kotani, Y., et al. A metabolomic approach to lung cancer. Lung Cancer 74 (2011), 284–292, 10.1016/j.lungcan.2011.02.008.
8. [8] Wen, T., Gao, L., Wen, Z., Wu, C., Tan, C.S., Toh, W.Z., et al. Exploratory investigation of plasma metabolomics in human lung adenocarcinoma. Mol. BioSyst. 9 (2013), 2370–2378, 10.1039/c3mb70138g.
9. [9] Lindon, J.C., Holmes, E., Nicholson, J.K., Metabonomics and its role in drug development and disease diagnosis. Expert. Rev. Mol. Diagn. 4 (2004), 189–199, 10.1586/14737159.4.2.189.
10. [10] Chen, J.-H., Enloe, B.M., Fletcher, C.D., Cory, D.G., Singer, S., Biochemical analysis using high-resolution magic angle spinning NMR spectroscopy distinguishes lipoma-like well-differentiated liposarcoma from normal fat. J. Am. Chem. Soc. 123 (2001), 9200–9201, 10.1021/ja016182u.
11. [11] Ramautar, R., Demirci, A., de Jong, G.J., Capillary electrophoresis in metabolomics. TrAC Trends Anal. Chem. 25 (2006), 455–466, 10.1016/j.trac.2006.02.004.
12. [12] Gosetti, F., Mazzucco, E., Gennaro, M.C., Marengo, E., Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 927 (2013), 22–36, 10.1016/j.jchromb.2012.12.003.
13. [13] Niu, Y., Jiang, Y., Xu, C., Wang, X., Liu, Y., Zhao, H., et al. Preliminary results of metabolite in serum and urine of lung cancer patients detected by metabolomics. Zhongguo Fei Ai Za Zhi 15 (2012), 195–201, 10.3779/j.issn.1009-3419.2012.04.01.
14. [14] González-Domínguez, R., García-Barrera, T., Gómez-Ariza, J.L., Using direct infusion mass spectrometry for serum metabolomics in Alzheimer's disease. Anal. Bioanal. Chem. 406 (2014), 7137–7148, 10.1007/s00216-014-8102-3.
15. [15] Draper, J., Lloyd, A.J., Goodacre, R., Beckmann, M., Flow infusion electrospray ionisation mass spectrometry for high throughput, non-targeted metabolite fingerprinting: a review. Metabolomics 9 (2012), 4–29, 10.1007/s11306-012-0449-x.
16. [16] González-Domínguez, R., García-Barrera, T., Gómez-Ariza, J.L., Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry. J. Pharm. Biomed. Anal. 98 (2014), 321–326, 10.1016/j.jpba.2014.05.023.
17. [17] Takahashi, H., Kai, K., Shinbo, Y., Tanaka, K., Ohta, D., Oshima, T., et al. Metabolomics approach for determining growth-specific metabolites based on Fourier transform ion cyclotron resonance mass spectrometry. Anal. Bioanal. Chem. 391 (2008), 2769–2782, 10.1007/s00216-008-2195-5.
18. [18] Favretto, D., Cosmi, E., Ragazzi, E., Visentin, S., Tucci, M., Fais, P., et al. Cord blood metabolomic profiling in intrauterine growth restriction. Anal. Bioanal. Chem. 402 (2012), 1109–1121, 10.1007/s00216-011-5540-z.
19. [19] Guo, Y., Wang, X., Qiu, L., Qin, X., Liu, H., Wang, Y., et al. Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry. Clin. Chim. Acta 414 (2012), 135–141, 10.1016/j.cca.2012.08.010.
20. [20] Maeda, J., Higashiyama, M., Imaizumi, A., Nakayama, T., Yamamoto, H., Daimon, T., et al. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer, 10, 2010, 690, 10.1186/1471-2407-10-690.
21. [21] Carrola, J., Rocha, C.M., Barros, A.S., Gil, A.M., Goodfellow, B.J., Carreira, I.M., et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J. Proteome Res. 10 (2011), 221–230, 10.1021/pr100899x.
22. [22] Hanai, Y., Shimono, K., Matsumura, K., Vachani, A., Albelda, S., Yamazaki, K., et al. Urinary volatile compounds as biomarkers for lung cancer. Biosci. Biotechnol. Biochem. 76 (2012), 679–684, 10.1271/bbb.110760.
23. [23] Yang, Q., Shi, X., Wang, Y., Wang, W., He, H., Lu, X., et al. Urinary metabonomic study of lung cancer by a fully automatic hyphenated hydrophilic interaction/RPLC-MS system. J. Sep. Sci. 33 (2010), 1495–1503, 10.1002/jssc.200900798.
24. [24] Li, S., Wang, R., Zhang, M., Wang, L., Cheng, S., Proteomic analysis of non-small cell lung cancer tissue interstitial fluids. World J. Surg. Oncol., 11, 2013, 173, 10.1186/1477-7819-11-173.
25. [25] Jordan, K.W., Adkins, C.B., Su, L., Halpern, E.F., Mark, E.J., Christiani, D.C., et al. Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue-serum pairs. Lung Cancer 68 (2010), 44–50, 10.1016/j.lungcan.2009.05.012.
26. [26] Rocha, C.M., Barros, A.S., Gil, A.M., Goodfellow, B.J., Humpfer, E., Spraul, M., et al. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J. Proteome Res. 9 (2010), 319–332, 10.1021/pr9006574.
27. [27] Escribano Montaner, A., Moreno Galdó, A., Técnicas fibrobroncoscópicas especiales: lavado broncoalveolar, biopsia bronquial y biopsia transbronquial. An. Pediatr. 62 (2005), 352–366, 10.1157/13073249.
28. [28] Ho, W.E., Xu, Y.-J., Cheng, C., Peh, H.Y., Tannenbaum, S.R., Wong, W.S.F., et al. Metabolomics reveals inflammatory-linked pulmonary metabolic alterations in a murine model of house dust mite-induced allergic asthma. J. Proteome Res. 13 (2014), 3771–3782, 10.1021/pr5003615.
29. [29] Haferburg, G., Kothe, E., Microbes and metals: interactions in the environment. J. Basic Microbiol. 47 (2007), 453–467, 10.1002/jobm.200700275.
30. [30] Evans, C.R., Karnovsky, A., Kovach, M.A., Standiford, T.J., Burant, C.F., Stringer, K.A., Untargeted LC-MS metabolomics of bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health. J. Proteome Res. 13 (2014), 640–649, 10.1021/pr4007624.
31. [31] Rai, R.K., Azim, A., Sinha, N., Sahoo, J.N., Singh, C., Ahmed, A., et al. Metabolic profiling in human lung injuries by high-resolution nuclear magnetic resonance spectroscopy of bronchoalveolar lavage fluid (BALF). Metabolomics 9 (2012), 667–676, 10.1007/s11306-012-0472-y.
32. [32] Park, Y., Guidot, D.M., Martin, G.S., Brown, L.A., Lennox, J., Jones, D.P., Metabolomics of bronchoalveolar lavage differentiate healthy HIV-1-infected subjects from controls. AIDS Res. Hum. Retrovir. 30 (2014), 579–585, 10.1089/aid.2013.0198.
33. [33] Wolak, J.E., Esther, C.R., O'Connell, T.M., Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients. Biomarkers 14 (2009), 55–60, 10.1080/13547500802688194.
34. [34] Katajamaa, M., Oresic, M., Data processing for mass spectrometry-based metabolomics. J. Chromatogr. A 1158 (2007), 318–328, 10.1016/j.chroma.2007.04.021.
35. [35] Smith, C.A., Want, E.J., O'Maille, G., Abagyan, R., Siuzdak, G., XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78 (2006), 779–787, 10.1021/ac051437y.
36. [36] Veselkov, K.A., Vingara, L.K., Masson, P., Robinette, S.L., Want, E., Li, J.V., et al. Optimized preprocessing of ultra-performance liquid chromatography/mass spectrometry urinary metabolic profiles for improved information recovery. Anal. Chem. 83 (2011), 5864–5872, 10.1021/ac201065j.
37. [37] van den Berg, R.A., Hoefsloot, H.C.J., Westerhuis, J.A., Smilde, A.K., van der Werf, M.J., Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics, 7, 2006, 142, 10.1186/1471-2164-7-142.
38. [38] Xia, J., Wishart, D.S., MetPA: a web-based metabolomics tool for pathway analysis and visualization. Bioinformatics 26 (2010), 2342–2344, 10.1093/bioinformatics/btq418.
39. [39] Cascino, A., Muscaritoli, M., Cangiano, C., Conversano, L., Laviano, A., Ariemma, S., et al. Plasma amino acid imbalance in patients with lung and breast cancer. Anticancer Res. 15 (1995), 507–510 (http://www.scopus.com/inward/record.url?eid=2-s2.0-0029045178&partnerID=tZOtx3y1).
40. [40] Proenza, A.M., Oliver, J., Palou, A., Roca, P., Breast and lung cancer are associated with a decrease in blood cell amino acid content. J. Nutr. Biochem. 14 (2003), 133–138, 10.1016/S0955-2863(02)00225-5.
41. [41] Lai, H.-S., Lee, J.-C., Lee, P.-H., Wang, S.-T., Chen, W.-J., Plasma free amino acid profile in cancer patients. Semin. Cancer Biol. 15 (2005), 267–276, 10.1016/j.semcancer.2005.04.003.
42. [42] Kubota, A., Meguid, M.M., Hitch, D.C., Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors. Cancer 69 (1992), 2343–2348 (http://www.scopus.com/inward/record.url?eid=2-s2.0-0026529517&partnerID=tZOtx3y1).
43. [43] Naini, A.B., Dickerson, J.W.T., Brown, M.M., Preoperative and postoperative levels of plasma protein and amino acid in esophageal and lung cancer patients. Cancer 62 (1988), 355–360 (http://www.scopus.com/inward/record.url?eid=2-s2.0-0023928169&partnerID=tZOtx3y1).
44. [44] van den Heuvel, A.P.J., Jing, J., Wooster, R.F., Bachman, K.E., Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol. Ther. 13 (2012), 1185–1194, 10.4161/cbt.21348.
45. [45] Blomback, B., Methods in Enzymology. 1967, Academic Press, New York, USA, C·Hirs.
46. [46] Mashima, T., Seimiya, H., Tsuruo, T., De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer 100 (2009), 1369–1372, 10.1038/sj.bjc.6605007.
47. [47] De Backer, D., Creteur, J., Zhang, H., Norrenberg, M., Vincent, J.L., Lactate production by the lungs in acute lung injury. Am. J. Respir. Crit. Care Med. 156 (1997), 1099–1104 (http://www.scopus.com/inward/record.url?eid=2-s2.0-0030879973&partnerID=tZOtx3y1).
48. [48] Ho, W.E., Xu, Y.-J., Xu, F., Cheng, C., Peh, H.Y., Tannenbaum, S.R., et al. Metabolomics reveals altered metabolic pathways in experimental asthma. Am. J. Respir. Cell Mol. Biol. 48 (2013), 204–211, 10.1165/rcmb.2012-0246OC.
49. [49] Ho, W.E., Xu, Y.-J., Xu, F., Cheng, C., Peh, H.Y., Huang, S.-M., et al. Anti-malarial drug artesunate restores metabolic changes in experimental allergic asthma. Metabolomics 11 (2014), 380–390, 10.1007/s11306-014-0699-x.
50. [50] Moreno-Sánchez, R., Marín-Hernández, A., Saavedra, E., Pardo, J.P., Ralph, S.J., Rodríguez-Enríquez, S., Who controls the ATP supply in cancer cells? Biochemistry lessons to understand cancer energy metabolism. Int. J. Biochem. Cell Biol. 50 (2014), 10–23, 10.1016/j.biocel.2014.01.025.
51. [51] Matsumoto, S.S., Raivio, K.O., Seegmiller, J.E., Adenine nucleotide degradation during energy depletion in human lymphoblasts. Adenosine accumulation and adenylate energy charge correlation. J. Biol. Chem. 254 (1979), 8956–8962 (http://www.scopus.com/inward/record.url?eid=2-s2.0-0018664862&partnerID=tZOtx3y1).
52. [52] Guidotti, A., Konkel, D.R., Ebstein, B., Corda, M.G., Wise, B.C., Krutzsch, H., et al. Isolation, characterization, and purification to homogeneity of a rat brain protein (GABA-modulin). Proc. Natl. Acad. Sci. 79 (1982), 6084–6088, 10.1073/pnas.79.19.6084.
53. [53] Mogensen, I.B., Schulenberg, H., Hansen, H.O., Spener, F., Knudsen, J., A novel acyl-CoA-binding protein from bovine liver. Effect on fatty acid synthesis. Biochem. J. 241 (1987), 189–192 (http://www.scopus.com/inward/record.url?eid=2-s2.0-0023148729&partnerID=tZOtx3y1).
54. [54] Chen, Z., Agerberth, B., Gell, K., Andersson, M., Mutt, V., Ostenson, C.-G., et al. Isolation and characterization of porcine diazepam-binding inhibitor, a polypeptide not only of cerebral occurrence but also common in intestinal tissues and with effects on regulation of insulin release. Eur. J. Biochem. 174 (1988), 244–245, 10.1111/j.1432-1033.1988.tb14089.x.
55. [55] Rasmussen, J.T., Faergeman, N.J., Kristiansen, K., Knudsen, J., Acyl-CoA-binding protein (ACBP) can mediate intermembrane acyl-CoA transport and donate acyl-CoA for β-oxidation and glycerolipid synthesis. Biochem. J. 299 (1994), 165–170 (http://www.scopus.com/inward/record.url?eid=2-s2.0-0028296147&partnerID=tZOtx3y1).
56. [56] Liu, Y., Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 9 (2006), 230–234, 10.1038/sj.pcan.4500879.
57. [57] Gazdar, A.F., Zweig, M.H., Carney, D.N., Van Steirteghen, A.C., Baylin, S.B., Minna, J.D., Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res. 41 (1981), 2773–2777.
58. [58] Heber, D., Chlebowski, R.T., Ishibashi, D.E., Herrold, J.N., Block, J.B., Abnormalities in glucose and protein metabolism in noncachectic lung cancer patients. Cancer Res. 42 (1982), 4815–4819 (http://www.scopus.com/inward/record.url?eid=2-s2.0-0020426260&partnerID=tZOtx3y1).
59. [59] Chang, A.K., Barrettconnor, E., Edelstein, S., Low plasma cholesterol predicts an increased risk of lung-cancer in elderly women. Prev. Med. (Baltimore) 24 (1995), 557–562, 10.1006/pmed.1995.1089.
60. [60] Glunde, K., Jie, C., Bhujwalla, Z.M., Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 64 (2004), 4270–4276, 10.1158/0008-5472.CAN-03-3829.
61. [61] Jelonek, K., Ros, M., Pietrowska, M., Widlak, P., Cancer biomarkers and mass spectrometry-based analyses of phospholipids in body fluids. Clin. Lipidol. 8 (2013), 137–150, 10.2217/clp.12.79.
62. [62] Banez-Coronel, M., de Molina, A., Rodriguez-Gonzalez, A., Sarmentero, J., Ramos, M., Garcia-Cabezas, M., et al. Choline kinase alpha depletion selectively kills Tumoral cells. Curr. Cancer Drug Targets 8 (2008), 709–719, 10.2174/156800908786733432.